Coherus BioSciences reports Victory in Pegfilgrastim Patent Dispute (the 707 patent)

Coherus BioSciences reports Victory in Pegfilgrastim Patent Dispute (the 707 patent)

Tuesday, July 30, 2019   DrugName : pegfilgrastim 

Coherus BioSciences, Inc., announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the District of Delaware that Coherus’ UDENYCA (pegfilgrastim-cbqv), a pegfilgrastim biosimilar, does not infringe Amgen’s asserted patent. Coherus launched UDENYCA in the United States in January 2019.

 

THE 707 PATENT

As previously reported, on May 10, 2017, Amgen filed a patent infringement complaint under the Biologics Price Competition and Innovation Act (“BPCIA”) against Coherus asserting U.S. Patent 8,273,707 (“the ’707 patent”). In June 2017, Coherus filed a motion to dismiss the lawsuit on the grounds that Coherus’ UDENYCA could not be found to infringe Amgen’s patent. The District Court granted Coherus’ motion to dismiss the case in March 2018. Amgen subsequently appealed, and the parties participated in an oral argument before the Federal Circuit on May 8, 2019.

The Federal Circuit’s precedential opinion affirmed the District Court’s judgment in Coherus’ favor. The Federal Circuit held that the doctrine of prosecution history estoppel barred Amgen from succeeding on its infringement claim and affirmed the District Court’s dismissal.

“We are pleased by the Federal Circuit’s precedential decision and have always been confident that the District Court’s decision would be affirmed on appeal,” said Thomas Fitzpatrick, Coherus’ Chief Legal Officer. “We are particularly pleased to continue our mission to successfully lower healthcare costs and expand patients’ access to life-saving drugs.”

Key Facts

    •  News Category

      Other Product News 
      Product Development 
      Intellectual Property 
      Legal And Regulatory 

    Ingredients in these cialis price cute-n-tiny.com capsules have mind-alerting ingredients, resulting in low stress levels and enhancing mental endurance. There is a sexual stimulant for women? The Pfizer Company is already working on such a medicine as the order levitra canada , but for women. It is a natural anti-aging supplement and boosts generic discount levitra energy levels. The cialis canada generic best sexual firmness How is the Holistic Approach Different from the Usual Couple’s Therapy? The holistic approach is different because it focuses on spiritual, mental and physical health.

    •  Company

      Amgen Inc

    • Coherus BioSciences Inc

    •  Country

      North America > United States of America 

Leave a Reply

Your email address will not be published. Required fields are marked *

51 + = 53